According to statistics, about 20 million Americans suffer from some form of thyroid disease. The most common form of hyperthyroidism is Graves' disease, which can cause various symptoms, including extreme anxiety and fatigue, shaking hands, sweating and weight loss. This disease usually causes eye swelling and protrusion, which is called eye disease in medicine and affects up to 50% of Graves victims.
Professor Raymond Douglas and Professor Terry Smith studied for nearly 15 years and invented a drug called Teprotumumab. Teprotumumab can target molecules that stop eye tissues and fight Graves' ophthalmopathy.
This month, a paper written by two surgeons was published in the New England Journal of Medicine, which has a prominent position in the medical field. It is the first time to prove that drugs can replace thyroid eye surgery. Teprotumumab can not only be used as an antibody to stop the progress of the disease, but also show that it can completely reverse the disease. FDA designated it as a "breakthrough" therapy, which will completely change the medical field of thyroid ophthalmopathy. Twenty-two centers around the world participated in clinical trials, making it the largest biological trial of the disease in the world. Professor Raymond Douglas, as the chief researcher of the national Teprotumumab trial, will supervise the final trial in Los Angeles later this month.
"The cooperation between Professor Raymond Douglas and Professor Terry Smith has successfully completely changed the rules of the game in the treatment of thyroid-associated eye diseases. Teprotumumab not only replaced surgery, but also was the first and only drug that was proved to reverse the disease. The medical community has accepted Teprotumumab's treatment plan, which will certainly be welcomed by patients with Graves' disease. Cedars-Sinai Medical Center is honored to be one of the centers of this extraordinary therapy, "said Dr. BruceL.Gewertz, director of surgery and deputy director of academic affairs at Cedars-Sinai University.
Teprotumumab will be listed for the first time as soon as next year and will appear in six major medical centers in the United States, including Cedars-Sinai Medical Center in Los Angeles and LaPeer Health Center in Beverly Hills. Professor Raymond Douglas also received patients from all over the United States and around the world in California and Shanghai, China.
Professor Raymond Douglas is an internationally renowned expert in eye plastic surgery and orbital diseases, and has rich clinical treatment experience. Among them, it has made outstanding contributions to thyroid-associated ophthalmopathy, and its surgical treatment and scientific research level are in the leading position in the world, and its annual operation volume is also in the forefront in the United States.
Professor Raymond Douglas has developed the world's first new drug to treat thyroid ophthalmopathy, and he is also the first person to propose a personalized minimally invasive treatment scheme for thyroid ophthalmopathy, which aims to make the operation safer, reduce scar formation and recover faster with minimal trauma. The treatment plan has won the praise of the majority of patients.
Professor Raymond Douglas currently holds various positions, including co-founder and committee member of the International Society of Thyroid Ophthalmology, member of the American Society of Ophthalmology Plastic Surgery, member of the Young Doctors Training Program Committee of the American Society of Ophthalmology Plastic Surgery, professor of Kellogg Eye Hospital affiliated to the University of Michigan, member of the American Beauty Association, member of the Scientific Committee of the National Thyroid Ophthalmology Foundation, member of the American Thyroid Association, director of the Training Committee of the Asia-Pacific Ophthalmology Society, member of the American Ophthalmology Society, reviewer of the American Journal of Ophthalmology, and reviewer of the Journal of Clinical Endocrinology and Metabolism.
After years of education and training in institutions of higher learning, Professor Raymond Douglas has a solid surgical foundation and strong scientific research ability. Specializes in personalized minimally invasive treatment of thyroid ophthalmopathy and other orbital diseases, surgical correction of various eyelid failures, and Mohs repair surgery after eye skin cancer. ?
Professor Frederick Terry Smith. L.Huetwell, a world-renowned endocrinologist at the Institute of Ophthalmology and Visual Sciences of the University of Michigan, has studied Graves' disease, ocular manifestations and related autoimmune diseases for more than 20 years. Terry Smith (Terry? Professor Smith's laboratory proposed for the first time that the unique molecular characteristics of eye tissues are easily influenced by the inflammatory response of Graves' disease.
Professor Terry Smith received a bachelor's degree in medicine from the University of Missouri School of Medicine, and completed residency practice at the University of Illinois in Chicago and Sinai Hospital in Baltimore. After that, he completed advanced courses in biophysics and molecular biochemistry at Columbia University in new york and clinical endocrinology at the Pritzker School of Medicine at the University of Chicago.
Professor Terry Smith is the author of more than 150 articles and books, and has obtained five patents for his research results. He was elected as the chief scientific officer of the Graves Foundation of the National Orbital Society and served as a reviewer of many scientific journals. Since 1983, Terry Smith (Terry? Professor Smith) is continuously funded by the National Institutes of Health and the Veterans Administration.